HIV Drug Resistance
ReFocus I ™ is a distinctive genotyping assay that is uniquely designed to provide accurate and rapid diagnostic information relevant to the management of HIV drug resistance and / or virologic failure on antiretroviral therapy (ART). The HIVDR RTI assay detects actionable drug resistance mutations (DRMs) in the reverse transcriptase gene of the HIV-1 genome which affect susceptibility to the NNRTI and/or NRTI ARV drug classes.
The ReFocus I assay is an in vitro semi-quantitative (RT)-PCR (qPCR) assay for the amplification and detection of the common DRMs K65R, K103N, V106M, Y181C, M184V/I and G190A, in viral RNA samples extracted from plasma of HIV-infected individuals with viral loads ranging from 2,000 to 750,000 copies / mL.
Please enquire below about the availability of this product.